MAF1 and cardiac hypertrophy: Moreover, compared with the Ad-GFP-injected mice at 4 weeks after AB, the Maf1-overexpressing mice exhibited significantly attenuated cardiac hypertrophy and pulmonary edema, as shown by decreased heart size (about 30%) (Figure 3C), cardiomyocyte surface area (about 53%) (Figure 3K-L), heart/body weight ratio (about 30%) (Figure 3D), heart weight/tibia length ratio (about 19%) (Figure S3B), lung weight/body weight (about 43%) (Figure 3E) and lung weight/tibia length ratio (about 35%) (Figure S3C).